Immunic, Inc. to Announce Financial Results for the Second Quarter EndedJune 30, 2024, and Provide Corporate Update – Webcast to be Held at 8:00 am ET on August 8, 2024 – NEW YORK, August 1, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic infl [ … ]

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec  – Senior Executive and Thought Leader in Brain Health with Nearly Three Decades of Global Pharmaceutical Experience –  – Served as Neuroimmunology Franchise Head Responsible for Roche’s Blockbuster Launch of Multiple Scl [ … ]